Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Endocrinology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Endocrinology Other
    Study Shows Monitoring Bone Density in Older Women Unnecessary, Potentially Misleading - (DGNews)
    Children With Subclinical Hypothyroidism Do Not Experience Increase in Height With Thyroxine Therapy: Presented at ENDO 09 - (DGDispatch)
    Testosterone Therapy Improves Metabolic Syndrome, Liver Steatosis in Hypogonadal Men: Presented at ENDO 09 - (DGDispatch)
    Complement Component 3 Linked to Metabolic Syndrome in Patients Receiving Statins: Presented at ENDO 09 - (DGDispatch)
    Isolated Familial Hypogonadotropic Hypogonadism and a GNRH1 Mutation - (N Engl J Med)

    News archive

     Recent webcasts/CME - Endocrinology Other
    • Matching Treatment to Need in Type 2 Diabetes: Using Incretin-Based Oral Therapies Across the Clinical Spectrum
    • Achieving Glycemic Control After Standard Therapy Has Failed
    • Management of New Diabetes Case With Compromised Renal Function
    • Luteal Support in Reproduction
      Diagnosis of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone

      Webcasts/CME archive

       Recent cases - Endocrinology Other
        Food-Dependent Cushing's Syndrome
        Parathyroid Apoplexy, the Explanation of Spontaneous Remission of Primary Hyperparathyroidism: A Case Report
        Deficiency of Growth Hormone in an Adult Man Case of Idiopathic Adrenocorticotropin Deficiency
        Polycystic Ovary Syndrome and Prolactinoma Association
        Improvement of the Diabetic Foot Upon Testosterone Administration to Hypogonadal Men with Peripheral Arterial Disease. Report of Three Cases

        Cases archive
          




        my personal edition > endocrinology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pegvisomant Normalizes Insulin-like Growth Factor-I in Acromegaly: Presented at AACE

        By Paula Moyer

        SAN DIEGO, CA -- May 21, 2003 -- Patients with acromegaly will respond to pegvisomant (Somavert) even if they have not responded optimally to octreotide (Sandostatin), according to findings presented here on May 16th at the American Association of Clinical Endocrinologists 12th Annual Meeting and Clinical Congress.

        "Pegvisomant is useful in the treatment of acromegaly regardless of a patient's prior outcome with octreotide," said Mary Lee Vance, MD, professor of internal medicine, division of endocrinology, University of Virginia, Charlottesville, Va. "It normalized insulin-like growth factor-I [IGF-I] in more than 90% of patients who had been receiving octreotide."

        Previous studies have shown that the IGF-I receptor inhibitor pegvisomant, normalizes insulin-like IGF-I levels in up to 97% of patients (Eur J Endocrinol 2003; Apr. 148[Suppl 2]:S027-32), an effect seen in 20% to 68% of patients treated with octreotide, which reduces growth hormone (GH) and IGF-I levels.

        The researchers reviewed the records of 109 patients who had received pegvisomant in a long-term extension trial. Of these, 44 had received octreotide subcutaneously up to the time of enrollment.

        They compared IGF-I concentrations at several time points to determine each patient's response to octreotide, their treatment-free baseline IGF-I concentrations, and response to pegvisomant.

        Ninety-three percent of patients had IGF-I concentrations within the normal range for their age after undergoing pegvisomant treatment. By contrast, 39% had normal concentrations while receiving octreotide treatment.

        Mean difference in IGF-I concentrations from baseline to screening was 29%, reflecting the treatment effect of octreotide. The mean difference in those concentrations from baseline to the final study visit was 50%, a reflection of the treatment effect seen with pegvisomant.

        On the basis of these findings, Dr. Vance and her co-investigators concluded that pegvisomant's mechanism of action results in effective biochemical control of acromegaly. For most patients in whom octreotide did not result in optimal control, pegvisomant lowered and normalized IGF-I concentrations, she reported.

        The study was sponsored by Pfizer, Inc.,New York, NY.


        [Study title: Normalization of Insulin-Like Growth Factor-I With Pegvisomant in a Subset of Patients With Acromegaly Previously Treated With Octreotide. Abstract 41]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send